CYP2C19 and coronary artery disorder: This treatment showed promise in stabilizing renal function and improving symptoms associated with Fabry disease in this subset of patients.[26] The study by Erlinge et al demonstrated that point-of-care CYP2C19 genetic testing to determine clopidogrel metabolizer status in patients with CAD did not significantly reduce major adverse cardiovascular events compared to standard treatment without genetic testing.[27] The findings suggested limited clinical benefit of routine genetic testing for guiding clopidogrel therapy in this patient population.